Table 4.
Echocardiography and functional parameters.
| Variable | Baseline | Placebo | Trimetazidine | p-Value * |
|---|---|---|---|---|
| PAPs, mmHg | 77 ± 22 | −7 ± 20 | −6 ± 16 | NS |
| PAPm, mmHg | 45 ± 11 | −0.6 ± 11.0 | −1.3 ± 9.9 | NS |
| RV time-velocity integral, cm | 12.6 ± 3.1 | 1.1 ± 3.5 | 1.2 ± 3.1 | NS |
| TVI TR, cm | 135 ± 29 | −3 ± 27 | 2 ± 27 | NS |
| RV diastolic area, cm2 | 29 ± 10 | 0.1 ± 4.1 | −1.7 ± 4.0 | 0.033 |
| RV systolic area, cm2 | 20.5 ± 8.1 | −0.2 ± 4.2 | −1.4 ± 4.0 | NS |
| RV diastolic volume, cm3 | 94.8 ± 54.8 | −1.5 ± 22.8 | −7.5 ± 18 | NS |
| RV systolic volume, cm3 | 56 ± 36 | −2.6 ± 20 | −4.4 ± 14.9 | NS |
| TAPSE, cm | 16.6 ± 4.9 | −0.02 ± 3.3 | 0.89 ± 3.53 | NS |
| RA area, cm2 | 26.7 ± 9.9 | −0.9 ± 5.3 | −1.1 ± 3.1 | NS |
| Oxygen saturation (SaO2), % | 96 ± 3 | −0.15 ± 2.05 | 0.15 ± 1.8 | NS |
| 6-min walk test, meters | 421 ± 107 | −2.6 ± 77.4 | 16.9 ± 62.5 | 0.023 |
| Borg dyspnea index, int | 4.4 ± 2.5 | 0.1 ± 2.3 | −0.3 ± 1.8 | NS |
* Data represent changes from baseline.